Genetic Analysis

GEAN

NO0010692130

Healthcare Facilities & Services

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.64 ^NOK	-4.48%		+18.52%	-24.71%

Feb. 29	Genetic Analysis AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
Feb. 26	Genetic Analysis AS Announces CE-IVD Marking for its GA-map Sample Collection Kit	CI

Genetic Analysis AS Announces Changes in Members of Nomination Committee

May 11, 2023 at 10:49 am EDT

Genetic Analysis AS held its Annual General Meeting on May 11, 2023 approved Svein Lien and Eilert Aamodt were elected as members of nomination committee.

Latest news about Genetic Analysis

Genetic Analysis AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Genetic Analysis AS Announces CE-IVD Marking for its GA-map Sample Collection Kit	Feb. 26	CI
Genetic Analysis Partners Up to Enter the Consumer Market with Ga-Map	Dec. 21	CI
Genetic Analysis AS Announces Resignation of Staffan Strömberg from the Board of Directors	Nov. 02	CI
Genetic Analysis AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Genetic Analysis AS Provides Earnings Guidance for the Year 2023, 2024, and 2025	Nov. 02	CI
Genetic Analysis AS Launches the GA-map® Discovery - New Microbiome Profiling Service Offering Directed to Research Customers in the Academia and Microbiome Industry	23-10-24	CI
Genetic Analysis AS Announces Development Project Initiated for A New Companion Diagnostic Test	23-10-12	CI
Genetic Analysis AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Genetic Analysis Secures Partnership Deal for US Launch of GA-map Microbiome Test	23-08-25	MT
Genetic Analysis AS Enters an Agreement with Elta90 Group to Distribute and Launch Ga-Map[®] Technology in the Balkan Region	23-06-08	CI
Genetic Analysis AS Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Genetic Analysis AS Announces Changes in Members of Nomination Committee	23-05-11	CI
Genetic Analysis AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-17	CI
Genetic Analysis AS Announces Executive Changes	23-01-31	CI
Genetic Analysis Wins Approval for Gut Microbiome Test in Thailand	23-01-19	MT
Genetic Analysis as Achieves Thai Fda License for Ga-Map[®] Dysbiosis Test in Thailand	23-01-19	CI
Genetic Analysis Strikes Distribution Deal For Gut Microbiota Test In Europe	22-11-07	MT
Genetic Analysis as Enters an Agreement with A Major Diagnostic Company for Distribution of GA-map in Europe	22-11-07	CI
Genetic Analysis AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-01	CI
Genetic Analysis AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-18	CI
Genetic Analysis and Servatus Enter Strategic Collaboration Agreement to Develop New Microbiome Diagnostostic and Therapeutic Solutions	22-06-22	CI
Genetic Analysis AS and Omnigene Medical Technologies Ltd. Enter a Distribution Agreement to Launch GA-mA-map	22-05-19	CI
Genetic Analysis AS Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Genetic Analysis AS Announces Board Changes	22-04-29	CI

Genetic Analysis AS is a Norway-based company active in the field of molecular diagnostics of diseases related to large and small intestine (gut) imbalances. The Company has developed a DNA-based platform technology that allows for simultaneous analysis of a number of similar (but not identical) gene fragments in one reaction. The GA-map platform technology utilizes common and variable DNA sequences within the 16S rRNA gene of the bacteria to characterize and identify the different bacteria. The technology makes it possible to generate profiles of a person's microbiota and correlate that profile to different health conditions.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
GENETIC ANALYSIS	-24.71%	2.44M
SONIC HEALTHCARE LIMITED	-17.89%	8.25B
RADNET, INC.	+39.20%	3.57B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B
SYNLAB AG	-8.06%	2.46B
DR. LAL PATHLABS LIMITED	-7.35%	2.38B
NEOGENOMICS, INC.	-12.61%	1.81B
FLEURY S.A.	-19.01%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B

Medical & Diagnostic Laboratories